Advanced Prostate Cancer Consensus Conference

Advanced Prostate Cancer
Consensus Conference: APCCC 2019

29-31 August 2019, Basel/Switzerland

Slides

Session 1: Molecular biomarkers and novel imaging in APC

Talk 1: State of the art on molecular characterization in advanced prostate cancer (APC)
-Non-metastatic prostate cancer
-Metastatic castration-naïve
-Metastatic CRPC
Pritchard

Talk 2: Clinical utility of molecular markers
De Bono

Talk 3: Advantages and pitfalls of PSMA PET/CT in APC imaging - Advantages
Fanti

Talk 4: Advantages and pitfalls of PSMA PET/CT in APC imaging - Pitfalls
Davis

Session 2: Node-positive prostate cancer (N1 but M0)

Talk 1: Node-positive prostate cancer (N1 but M0) - Surgery Options
Murphy

Talk 2: Node-positive prostate cancer (N1 but M0) - Radiation therapy options
Roach

Talk 3: Node-positive prostate cancer (N1 but M0) - Systematic therapy options
James

Talk 4: Synthesis – How best to treat cN1 prostate cancer
Fizazi

Talk 5: How to treat men with pathological node positive (pN1, cM0) prostate cancer?
Bossi

Session 3: PSA recurrence after radical local therapy and oligometastatic prostate cancer

Talk 1: Management of men with PSA recurrence after radical local radiation therapy
Feng

Talk 2: Management of men with PSA recurrence or persistence after prostatectomy
Evans

Talk 3: Oligometastatic prostate cancer – Definitions and concepts
Reiter

Talk 4: Treatment of de novo (synchronous) oligometastatic prostate cancer
Morris

Talk 5: Treatment of oligorecurrent (metachronous) prostate cancer after local therapy
Ost

Talk 6: Treatment of oligometastatic and oligoprogressive CRPC
Small

Session 4: Regional care (demographic and environmental factors)

Talk 1: Ethnicity and prognosis
Logothetis

Talk 2: Pharmaco-ethnicity and impact on treatment
Poon

Talk 3: Report and lessons learned from the consensus conference for developing countries
Maluf

Talk 4: Disparities in prostate cancer management in the U.S.
Morgans

Talk 5: The ageing population: Oncogeriatric assessment and treatment considerations
O'Sullivan

Extra Session: Movember

Outcomes Research – Ironman project
Morgans, Davis

Session 5: Management of metastatic castration-sensitive/naive prostate cancer

Talk 1: Testosterone measurement – Which test and when?
Gleave

Talk 2: Local treatment of the primary tumour (RT) in the metastatic situation
Bristow

Talk 3: Local treatment of the primary tumour (surgery) in the metastatic situation
Steuber

Talk 4: Which systemic therapy for which patient with newly diagnosed metastatic prostate cancer?
Sweeney

Talk 5: Addition of AR pathway inhibitors vs. docetaxel: Statisticians’ perspective
Sydes

Talk 6: Follow-up on ADT alone vs. ADT “plus”
Oh

Session 6: Management of castration-resistant prostate cancer (CRPC)

Talk 1: Definition and overview of treatment options in nmCRPC
Scher

Talk 2: Debate: Treatment of nmCRPC - Pros
Hussain

Talk 3: Debate: Treatment of nmCRPC - Cons
Higano

Talk 4: First-line mCRPC after ADT + Docetaxel or AR pathway inhibitor
Taplin

Talk 5: Subgroup analysis of mCRPC clinical trials
Halabi

Talk 6: PSMA targeted therapies
Hofman

Talk 7: Immunotherapy
Drake

Talk 8: PARP inhibition
Chi

Talk 9: Neuroendocrine spectrum: Diagnosis and treatment
Efstathiou

Session 7: Side effects of treatment and their management

Talk 1: Management of sexuality and incontinence issues in APC
Van Oort

Talk 2: Management of hot flushes
Frydenberg

Talk 3: Management of metabolic changes
Shore

Talk 4: Management of fatigue, cognition/dementia
Ryan

Talk 5: Optimal steroid use with abiraterone
Attard

Session 8: Bone and bone metastases

Talk 1: Prevention/Treatment of osteoporosis
Saad

Talk 2: Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC - Only for very select men with CRPC and bone metastases
Parker

Talk 3: Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC - For the majority of men with CRPC and bone metastases
Tombal

Talk 4: Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC - Synthesis – Best use of antiresorptivetherapy in CRPC
Smith

Talk 5: Radium-223 and bone health agents
Sartor

Talk 6: The flare phenomenon in bone-metastatic APC
Padhani

Session 9: The future of APC management

Talk 1: Wishes from a patient’s perspective
Millman

Talk 2: In locally advanced prostate cancer
Briganti

Talk 3: Looking into the Future: Oligometastatic Disease
Beltran

Talk 4: In polymetastatic prostate cancer
Oh

Talk 5: In imaging
Fanti

Talk 6: In biomarkers
Rubin

Talk 7: Global access to treatments
Fizazi